Korea United Pharm. recently received a patent registration from Brazil's Patent Office for its original technology for its high blood pressure treatment complex "Rosasc Tablet."
Under the acquisition of the technology patent this time, Korea United Pharm. has set the stage for its high blood pressure treatment to enter the Latin American market.
The company has developed a high blood pressure treatment complex called Rosasc Tablet, which includes "Amlodipine" affiliated with the calcium channel blocker (CCB) and "Lozaltan" affiliated with the Geotensin 2 receptor blocker (ARB), to improve patients' conformance to the drug.
In particular, double-layer molds were incorporated in the manufacturing process of Rosasc Tablet and the anti-oxidant propyl gallate was included. Through this process, the two ingredients were physically combined and drugs were prevented from interacting with each other, and the drugs were completed with minimal side effects.
Korea United Pharm., which obtained patents for its technologies in South Korea in 2014, has also registered patents in China, the Philippines and Russia.
"We will continue to expand our presence in overseas markets for high blood pressure treatment complex based on our excellent technical skills and securing overseas patents," said Korea United Pharm. CEO Kang Duk-young.